Equities

Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals NV

Actions
  • Price (CHF)56.30
  • Today's Change0.20 / 0.36%
  • Shares traded10.83k
  • 1 Year change-31.09%
  • Beta1.3231
Data delayed at least 15 minutes, as of Jan 26 2022 16:30 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.

  • Revenue in CHF (TTM)65.86m
  • Net income in CHF-11.02m
  • Incorporated--
  • Employees276.00
  • Location
    Cosmo Pharmaceuticals NVRiverside II, Sir John Rogerson's QuayDUBLIN IrelandIRL
  • Phone+353 18170370
  • Websitehttp://www.cosmopharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
COPN:SWX since
announced
Transaction
value
Cassiopea SpAAnnounced04 Oct 202104 Oct 2021Announced-29.18%228.73m
Data delayed at least 15 minutes, as of Jan 26 2022 16:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
RELIEF THERAPEUTICS Holding SA0.00-30.76m291.04m24.00--1.80-----0.0104-0.01040.000.03670.00-------28.70-22.60-32.74-24.44-------6,111.211.78-69.180.0693-------4.93------
Basilea Pharmaceutica AG112.50m-44.55m546.47m220.00------4.86-4.24-4.2410.53-6.680.53041.4419.13511,359.10-21.00-9.30-25.55-12.1878.2386.20-39.60-24.765.28-4.331.53---5.0219.2934.34--11.54--
Molecular Partners AG-100.00bn-100.00bn810.27m158.00--6.51----------3.85-----------22.74---27.52--96.59---216.66----0.0484---54.16-20.33-72.96--1.21--
Cosmo Pharmaceuticals NV65.86m-11.02m986.95m276.00--2.09--14.99-0.7645-0.76454.5726.850.10953.423.67248,521.60-1.83-2.38-1.89-2.4755.0064.02-16.74-19.6214.070.42110.3118---2.470.112667.64--26.09--
Dottikon ES Holding AG228.95m55.10m3.05bn658.0051.584.4140.4213.334.234.2317.4049.380.34290.41845.79358,287.908.256.449.357.2180.2282.3224.0717.593.38--0.00--25.2512.5157.7729.6731.33--
Siegfried Holding AG923.87m44.59m3.15bn3.43k66.423.8222.823.4110.7810.78221.20187.610.66992.104.21364,878.805.044.366.005.2121.2519.127.526.071.2191.020.246928.011.3911.95-25.12-2.40-6.16--
Idorsia Ltd36.19m-519.91m3.68bn636.00--15.34--101.79-3.17-3.170.22061.360.0265--7.21---38.13---42.12-------1,436.46-----147.580.8395--201.26--9.89------
BACHEM HOLDING AG464.00m98.35m4.06bn1.58k74.5515.0432.468.757.037.0333.1634.850.64771.246.30314,573.6013.739.0918.5311.6532.9531.0521.2017.500.433530.100.230174.8828.1414.0244.1219.6525.007.63
Data as of Jan 26 2022. Currency figures normalised to Cosmo Pharmaceuticals NV's reporting currency: Swiss Franc CHF

Institutional shareholders

10.82%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management Switzerland AGas of 12 Jan 2022524.55k2.99%
AMG Fondsverwaltung AGas of 30 Jun 2021314.77k1.79%
The Vanguard Group, Inc.as of 06 Jan 2022259.46k1.48%
Baillie Gifford & Co.as of 30 Nov 2021220.15k1.26%
Norges Bank Investment Managementas of 31 Dec 2020136.82k0.78%
Credit Suisse Asset Management (Schweiz) AGas of 31 Dec 2021123.00k0.70%
BlackRock Fund Advisorsas of 06 Jan 2022116.22k0.66%
Sp-Fund Management Co. Ltd.as of 30 Nov 202193.60k0.53%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 202057.54k0.33%
Bessemer Investment Management LLCas of 29 Oct 202152.83k0.30%
More ▼
Data from 31 Dec 2020 - 31 Dec 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.